Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (135)	9/25/2000 10:06:13 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 362

Thanks Nigel, Rick. Congratulation to all TTP long. Rick, I guess this time is full OK! Yippeeeeeee! EXP N! I did sold small part @17 (go figure) and captured half of initial investment. Was to slow (or smart, yes right!) in March. Walter told me recently (Jim S. told me the some two years ago) in S.F.: "do not sell (any stock) too quickly and too early". This time I am going to be good boy. :) Today we have second PII trial results (600 pts, two doses, highly stat. significant, positive and negative symptoms, excellent safety, ....), and enrollment COMPLETED in third PIII efficacy/safety PIII pivotal as well as three +400 pts long-term studies (various end-points). Based on this results and from first PIII trial NVS is getting ready for NDA file (1Q-'01 or early), they need long-term safety (+6 months). But this is already on the way, imo. Recently PFE made a big issue at AC meeting about Ziprasidone safety profile (low weight gain), while QTc remain at least as caution. Also drug efficacy was nothing of spectacular. Actually worse than risperidone. If NVS can show that Ilo have addition benefits (dementia, depression, ...) in three long-term studies, and there is good indication that it may have, than projection for 20-30% (and maybe 40%) of schizo market is warranted. All IMO only. Cheers, Miljenko